NCT05082805View on ClinicalTrials.gov

Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis

UnknownOBSERVATIONAL

Enrollment

400

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions

Rheumatoid ArthritisPsoriatic Arthritis

Trial Locations (1)

75007

Nordic Pharma, Paris

Sponsors

Lead Sponsor

Nordic Pharma SAS

All Listed Sponsors

lead

Nordic Pharma SAS

INDUSTRY

NCT05082805 - Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis | Biotech Hunter | Biotech Hunter